Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence
暂无分享,去创建一个
[1] R G Hoffmann,et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. , 1998, The American journal of psychiatry.
[2] Michele Zoli,et al. Molecular and Physiological Diversity of Nicotinic Acetylcholine Receptors in the Midbrain Dopaminergic Nuclei , 2001, The Journal of Neuroscience.
[3] D. Hamer,et al. An Improved Assay Shows No Association Between the CYP2A6 Gene and Cigarette Smoking Behavior , 1999 .
[4] Jaap Oosterlaan,et al. Pathological gambling: a comprehensive review of biobehavioral findings , 2004, Neuroscience & Biobehavioral Reviews.
[5] K. Matsuo,et al. Association of CYP2A6 Gene Deletion with Cigarette Smoking Status in Japanese Adults , 2003, Journal of epidemiology.
[6] D. Hamer,et al. Genetic and functional analysis of single nucleotide polymorphisms in the beta2-neuronal nicotinic acetylcholine receptor gene (CHRNB2). , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[7] D. Comings,et al. Reward deficiency syndrome: genetic aspects of behavioral disorders. , 2000, Progress in brain research.
[8] M. Ingelman-Sundberg,et al. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. , 2001, Biochemical and biophysical research communications.
[9] P. Sullivan,et al. The genetic epidemiology of smoking. , 1999, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[10] A. C. Collins,et al. Why some people smoke and others do not: new perspectives. , 1993, Journal of consulting and clinical psychology.
[11] O Pelkonen,et al. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. , 1992, Pharmacogenetics.
[12] Y. Funae,et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). , 1998, Pharmacogenetics.
[13] L. Peterson,et al. Evidence for metabolic activation of N'-nitrosonornicotine and N-nitrosobenzylmethylamine by a rat nasal coumarin hydroxylase. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[14] R. Freedman,et al. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics , 1992, Biological Psychiatry.
[15] T. Slotkin,et al. Short-Term Adolescent Nicotine Exposure has Immediate and Persistent Effects on Cholinergic Systems: Critical Periods, Patterns of Exposure, Dose Thresholds , 2003, Neuropsychopharmacology.
[16] M. Fiore,et al. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. , 1994, JAMA.
[17] R. Perera,et al. Nicotine replacement therapy for smoking cessation. , 2012, The Cochrane database of systematic reviews.
[18] C. Lerman,et al. Applying genetic approaches to the treatment of nicotine dependence , 2002, Oncogene.
[19] R. Tyndale,et al. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers , 2004, Tobacco Control.
[20] R. Tyndale,et al. Nicotine metabolism defect reduces smoking , 1998, Nature.
[21] W. Trager,et al. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[22] G. Chiara,et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs , 1996, Nature.
[23] C. Pomerleau,et al. Nicotine metabolite ratio as a predictor of cigarette consumption. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[24] R. Tyndale,et al. Mimicking Gene Defects to Treat Drug Dependence , 2000, Annals of the New York Academy of Sciences.
[25] Richard Doll,et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies , 2000, BMJ : British Medical Journal.
[26] P. McBride,et al. The health consequences of smoking. Cardiovascular diseases. , 1992, The Medical clinics of North America.
[27] D. Spruijt-Metz,et al. The meanings of smoking among Chinese American and Taiwanese American college students. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[28] N. Benowitz,et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity , 2004, Clinical pharmacology and therapeutics.
[29] N. Benowitz,et al. Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. , 2001, British journal of clinical pharmacology.
[30] K. Iwahashi,et al. Whole Deletion of CYP2A6 Gene (CYP2A6*4C) and Smoking Behavior , 2004, Neuropsychobiology.
[31] T Yamamoto,et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. , 2001, Pharmacogenetics.
[32] Jun Yokota,et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[33] L. Spear,et al. Nicotine-induced conditioned place preference in adolescent and adult rats , 2002, Physiology & Behavior.
[34] N. Martin,et al. The Genetics of Smoking Persistence in Men and Women: A Multicultural Study , 1999, Behavior genetics.
[35] M. Neale,et al. The Genetics of Smoking Initiation and Quantity Smoked in Dutch Adolescent and Young Adult Twins , 1999, Behavior genetics.
[36] Hiroshi Yamamoto,et al. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans , 2000, Clinical pharmacology and therapeutics.
[37] T. Baker,et al. Motivational influences on cigarette smoking. , 2004, Annual review of psychology.
[38] D. Bertrand,et al. Nicotine addiction: the possible role of functional upregulation. , 2002, Trends in pharmacological sciences.
[39] M. Jarvis,et al. The scientific case that nicotine is addictive , 2005, Psychopharmacology.
[40] C. Stockmeier,et al. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. , 1999, The Journal of pharmacology and experimental therapeutics.
[41] T. Kamataki,et al. Genetic polymorphism of CYP2A6 in relation to cancer. , 1999, Mutation research.
[42] J. Stengård,et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C‐oxidase , 1998, FEBS letters.
[43] M. Ingelman-Sundberg,et al. Characterisation and PCR‐based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population , 1999, FEBS letters.
[44] R. Tyndale,et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. , 2002, Biochemical and biophysical research communications.
[45] Vincenzo De Luca,et al. Evidence of Association between Smoking and α7 Nicotinic Receptor Subunit Gene in Schizophrenia Patients , 2004, Neuropsychopharmacology.
[46] C. Lerman,et al. Elucidating the role of genetic factors in smoking behavior and nicotine dependence , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[47] J. Hietala,et al. High levels of dopamine activity in the basal ganglia of cigarette smokers. , 2000, The American journal of psychiatry.
[48] C. S. Yang,et al. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes. , 1997, Carcinogenesis.
[49] N. Breslau,et al. Predicting smoking cessation and major depression in nicotine-dependent smokers. , 2000, American journal of public health.
[50] G. Coetzee,et al. Genetic variation of CYP2A6, smoking, and risk of cancer , 1999, The Lancet.
[51] Michael C Neale,et al. Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[52] O. Pelkonen,et al. Interindividual variability of coumarin 7-hydroxylation in a Turkish population , 2004, European Journal of Clinical Pharmacology.
[53] K. Cummings,et al. Predictors of smoking cessation in a cohort of adult smokers followed for five years. , 1997, Tobacco control.
[54] H. Yamazaki,et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). , 2003, Pharmacogenetics.
[55] S. Tiffany,et al. Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal , 2002, Psychopharmacology.
[56] Y. Funae,et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[57] T. Arinami,et al. Polymorphisms in genes involved in neurotransmission in relation to smoking. , 2000, European journal of pharmacology.
[58] E. Kharasch,et al. Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[59] H. Yamazaki,et al. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[60] S. Tokudome,et al. Effects of polymorphism in Promoter Region of Human CYP2A6 Gene (CYP2A6*9) on Expression Level of Messenger Ribonucleic Acid and Enzymatic Activity In Vivo and In Vitro , 2003, Clinical pharmacology and therapeutics.
[61] Jill C Mwenifumbo,et al. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. , 2005, Pharmacogenetics and genomics.
[62] K. Kellar,et al. Differential Regulation of Neuronal Nicotinic Receptor Binding Sites Following Chronic Nicotine Administration , 1997, Journal of neurochemistry.
[63] T. Kamataki,et al. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. , 1999, The Journal of pharmacology and experimental therapeutics.
[64] N. Benowitz. Pharmacology of nicotine: addiction and therapeutics. , 1996, Annual review of pharmacology and toxicology.
[65] G. Koob,et al. Dramatic decreases in brain reward function during nicotine withdrawal , 1998, Nature.
[66] W. Trager,et al. MECHANISM-BASED INACTIVATION OF HUMAN LIVER CYTOCHROME P 450 2 A 6 BY 8-METHOXYPSORALEN , 1997 .
[67] John T. Williams,et al. Nicotine activates and desensitizes midbrain dopamine neurons , 1997, Nature.
[68] T. Kamataki,et al. A novel single nucleotide polymorphism altering stability and activity of CYP2a6. , 2001, Biochemical and biophysical research communications.
[69] N. Rigotti,et al. Initial symptoms of nicotine dependence in adolescents , 2000, Tobacco control.
[70] R. Tyndale,et al. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[71] R. Tyndale,et al. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.
[72] D. Perry,et al. Subtype-Selective Up-Regulation by Chronic Nicotine of High-Affinity Nicotinic Receptors in Rat Brain Demonstrated by Receptor Autoradiography , 2003, Journal of Pharmacology and Experimental Therapeutics.
[73] T. Svensson,et al. Nicotine withdrawal in the rat: role of alpha7 nicotinic receptors in the ventral tegmental area. , 1999, Neuroreport.
[74] R. Tyndale,et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. , 2000, Molecular pharmacology.
[75] N. Benowitz,et al. Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. , 1998, The Journal of pharmacology and experimental therapeutics.
[76] M. Kitagawa,et al. CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic Activity* , 2001, The Journal of Biological Chemistry.
[77] M. Nakajima,et al. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. , 2002, British journal of clinical pharmacology.
[78] O. Pelkonen,et al. CYP2A6: a human coumarin 7-hydroxylase. , 2000, Toxicology.
[79] H. Coon,et al. Schizophrenia and Nicotinic Receptors , 1994, Harvard review of psychiatry.
[80] J. Rose,et al. Nicotine self-administration in animals and humans: similarities and differences , 1997, Psychopharmacology.
[81] T. Massey,et al. Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[82] Y. Funae,et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[83] G. Bepler,et al. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. , 2001, Toxicology.
[84] Tianhua Niu,et al. A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. , 2004, American journal of human genetics.
[85] Ming D. Li,et al. A genome-wide scan to identify loci for smoking rate in the Framingham Heart Study population , 2003, BMC Genetics.
[86] W. Berrettini,et al. The genetic determinants of smoking. , 2003, Chest.
[87] M. Loriot,et al. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. , 2001, Pharmacogenetics.
[88] M. Law,et al. The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. , 1997, British Journal of Cancer.
[89] M. Jarvis. Why people smoke , 2004, BMJ : British Medical Journal.
[90] Hiroshi Yamazaki,et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. , 2002, Pharmacogenetics.
[91] J. Henningfield,et al. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. , 1985, The Journal of pharmacology and experimental therapeutics.
[92] J. Changeux,et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine , 1998, Nature.
[93] R. Tyndale,et al. CYP2A6 genetic variation and potential consequences. , 2002, Advanced drug delivery reviews.
[94] M. Ingelman-Sundberg,et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity , 2002, Human mutation.
[95] W. Tan,et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. , 2003, Cancer research.
[96] N. Benowitz,et al. Nicotine renal excretion rate influences nicotine intake during cigarette smoking. , 1985, The Journal of pharmacology and experimental therapeutics.
[97] C. Pomerleau,et al. Early experiences with tobacco among women smokers, ex-smokers, and never-smokers. , 1998, Addiction.
[98] Hiroshi Yamamoto,et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans , 2001, Clinical pharmacology and therapeutics.
[99] Donna Spruijt-Metz,et al. Meanings of smoking and adolescent smoking across ethnicities. , 2004, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[100] N. Benowitz,et al. Metabolism of nicotine to cotinine studied by a dual stable isotope method , 1994, Clinical pharmacology and therapeutics.
[101] I Campbell,et al. Nicotine replacement therapy in smoking cessation. , 2003, Thorax.
[102] N. Martin,et al. Genetic and Social Determinants of Initiation and Age at Onset of Smoking in Australian Twins , 1999, Behavior genetics.
[103] W. Tan,et al. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population , 2001, International journal of cancer.
[104] J. Yokota,et al. CYP2A6 gene deletion reduces susceptibility to lung cancer. , 1999, Biochemical and biophysical research communications.
[105] J. Idle,et al. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[106] M. Jarvik,et al. Nicotine Blood Levels and Subjective Craving for Cigarettes , 2000, Pharmacology Biochemistry and Behavior.
[107] Majid Ezzati,et al. Estimates of global mortality attributable to smoking in 2000 , 2003, The Lancet.
[108] R. Tyndale,et al. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[109] B R Flay,et al. Stages in the development of adolescent smoking. , 2000, Drug and alcohol dependence.
[110] B. Green,et al. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. , 1999, Pharmacogenetics.
[111] R. Tyndale,et al. Decreasing smoking behaviour and risk through CYP2A6 inhibition. , 2003, Drug discovery today.
[112] N. Rigotti,et al. Recollections and repercussions of the first inhaled cigarette. , 2004, Addictive behaviors.
[113] R. Foxx,et al. Nicotine's role in smoking: an analysis of nicotine regulation. , 1983, Psychological bulletin.
[114] D. Naiman,et al. Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. , 2001, American journal of human genetics.
[115] O. Pomerleau. Individual differences in sensitivity to nicotine: Implications for genetic research on nicotine dependence , 1995, Behavior genetics.
[116] H. Yamazaki,et al. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. , 1992, Carcinogenesis.
[117] C. S. Yang,et al. Evidence for cytochrome P 450 2 A 6 and 3 A 4 as major catalysts for N 9-nitrosonornicotine α-hydroxylation by human liver microsomes , 1997 .
[118] N E Morton,et al. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit , 2000, Annals of human genetics.
[119] J. Changeux,et al. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors , 2003, The European journal of neuroscience.
[120] M. Loriot,et al. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. , 2000, Pharmacogenetics.
[121] M. Picciotto. Nicotine as a modulator of behavior: beyond the inverted U. , 2003, Trends in pharmacological sciences.
[122] O Pelkonen,et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism , 1999, FEBS letters.
[123] L Kruglyak,et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[124] B. Carter,et al. A meta-analytic review of the CYP2A6 genotype and smoking behavior. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[125] R. Tyndale,et al. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking , 2000, Clinical pharmacology and therapeutics.
[126] R. Tyndale,et al. Genetics of alcohol and tobacco use in humans , 2003, Annals of medicine.
[127] R. Tyndale,et al. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. , 2004, Pharmacogenetics.
[128] T. Svensson,et al. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: Putative role of α7 nicotinic receptors in the ventral tegmental area , 1998, Neuroscience.
[129] J. Yokota,et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. , 2004, Carcinogenesis.
[130] S. Fujishima,et al. Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema , 2003, Thorax.
[131] M. Le Moal,et al. Evidence for Enhanced Neurobehavioral Vulnerability to Nicotine during Periadolescence in Rats , 2003, The Journal of Neuroscience.
[132] M. Stitzer,et al. Cigarette brand-switching: effects on smoke exposure and smoking behavior. , 1988, The Journal of pharmacology and experimental therapeutics.
[133] H. Maeta,et al. Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. , 2003, Cancer research.
[134] J. Idle,et al. Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6 , 1998, European Journal of Clinical Pharmacology.
[135] J. Belluzzi,et al. Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats , 2004, Psychopharmacology.
[136] D. Kooy,et al. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area , 2003, Molecular Psychiatry.
[137] G. Koob. Neurobiology of Addiction: Toward the Development of New Therapies , 2000, Annals of the New York Academy of Sciences.